Patients with progressive, symptomatic, or recurrent desmoid tumors who received sorafenib have significantly improved progression-free survival (PFS) rates at 1 and 2 years compared with patients who received placebo, according to the results of a recent phase 3 trial.
Patients with progressive, symptomatic, or recurrent desmoid tumors who received sorafenib have significantly improved progression-free survival (PFS) rates at 1 and 2 years compared with patients who received placebo, according to the results of a recent phase 3 trial.
Desmoid tumors are neoplasms that originate from connective tissues, with common sites such as the abdominal wall, mesentery, and neurovascular bundle of the extremities. Although desmoid tumors normally do not metastasize, with the exception in Gardner syndrome, patients may have compromised vital organs, bowel obstruction, severe pain, and swelling.
There are numerous systemic treatment options that have been used for desmoid tumors: hormonal therapy, cytotoxic chemotherapy, and tyrosine kinase inhibitors; however, no standard of care has been accepted. In a retrospective analysis, sorafenib had emerged as a potential treatment option, with response rates of 25% and a tolerable safety profile. With these promising results already present, the current phase 3 trial sought to verify and evaluate the safety and efficacy of sorafenib for patients with desmoid tumors.
Eighty-seven patients with progressive, symptomatic, or recurrent desmoid tumors were enrolled in this trial and were randomly assigned to receive either sorafenib (400 mg daily) or placebo in a 2:1 ratio—50 patients received sorafenib and 37 patients received placebo. Treatment continued until disease progression, unacceptable adverse effects, or withdrawal of consent.
After a median follow-up period of 27.2 months, the PFS rates at 1 year were 89% and 46% for patients receiving sorafenib and placebo, respectively. PFS rates at 2 years were 81% and 36%, respectively (hazard ratio [HR], 0.13; 95% CI, 0.05-0.31; P < .0001). Of the patients in the sorafenib group, 12% of them had disease progression compared with 63% of those in the placebo group.
The objective response rate was 33% in the sorafenib group and 20% in the placebo group. Changes in the sum of target lesions also favored the sorafenib group (—26% vs –12% in the placebo group). Median time to response was 9.6 months in the sorafenib group and 13.3 months in the placebo group.
The most common cause for dose reductions in the sorafenib group were skin disorders, including rashes, pruritis, and palmar-plantar erythrodysesthesia syndrome. Discontinuation of treatment occurred in 20% of the patients receiving sorafenib and 0% of the patients receiving placebo. Grade 4 events that investigators suspected to be caused by sorafenib included thrombocytopenia and anemia, 2% each.
Based on the results of this phase 3 trial, investigators concluded that sorafenib was a safe and effective treatment option for patients with desmoid tumors. From the advantageous PFS rates and antitumor activity that it exerts, sorafenib may have a place in desmoid tumor as first-line or as subsequent therapy, they said.
Reference
Gounder MM, Mahoney MR, Van Tine BA et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More